Codiak Biosciences Return on Equity

Codiak Biosciences (CDAK) currently reports a ROE of -75.1%. That is below the Healthcare sector average of 11.15%. Use the charts on this page to explore Codiak Biosciences's ROE history and peer comparisons.

Codiak Biosciences's ROE of -75.1% is lower than the Healthcare sector average of 11.15%. That is roughly 773.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Codiak Biosciences's current -75.1% should be judged against Healthcare norms (sector average: 11.15%) and against CDAK's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -75.1%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.15%. From there, open related valuation or income-statement pages for Codiak Biosciences, and consider following CDAK for alerts when major investors trade the stock.

Codiak Biosciences is classified in the Healthcare sector. On ROE, it currently shows -75.1% versus a sector average near 11.15%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CDAK with unrelated industries.